Literature DB >> 1596887

Overexpression of cholecystokinin receptors in azaserine-induced neoplasms of the rat pancreas.

R H Bell1, E T Kuhlmann, R T Jensen, D S Longnecker.   

Abstract

Cholecystokinin (CCK) is a growth factor for normal pancreas. Numerous studies also suggest that CCK promotes pancreatic carcinogenesis in the rat. Our previous studies suggested that growth of preneoplastic pancreatic foci was stimulated by CCK more than that of normal pancreas. We hypothesized that such differential growth might be due to increased numbers of CCK receptors in neoplastic tissue. Azaserine-induced pancreatic carcinoma (DSL6) had an increased high-affinity CCK receptor binding capacity of 122 +/- 23 (SD) fmol/mg protein compared to 12 +/- 2 fmol/mg protein in normal pancreas (P less than 0.001). The Kd of the high-affinity site was 0.33 +/- 0.04 nM for carcinoma and 0.46 +/- 0.08 nM for normal pancreas (P less than 0.01). The amount of cholecystokinin octapeptide (CCK-8) bound to high-affinity receptor was 8.6 +/- 1.9 fmol/mg protein for DSL6 compared to 0.6 +/- 0.2 fmol/mg protein in normal pancreas (P less than 0.001). Azaserine-induced premalignant nodules were compared to remaining internodular pancreas. Nodules demonstrated a mean high-affinity CCK receptor binding capacity of 38 +/- 9 fmol/mg protein compared to 6 +/- 3 fmol/mg protein in internodular pancreas (P less than 0.001). The amount of CCK-8 bound to high-affinity receptor was 3.1 +/- 0.8 fmol/mg protein in nodules compared to 0.6 +/- 0.3 fmol/mg protein in internodular pancreas (P less than 0.001). Overexpression of high-affinity CCK-8 receptor in premalignant and malignant azaserine-induced tumors may result in a growth advantage relative to normal pancreas.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1596887

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  On the role of cholecystokinin in pancreatic cancer.

Authors:  M K Herrington; T E Adrian
Journal:  Int J Pancreatol       Date:  1995-04

2.  Investigational Strategies for Detection and Intervention in Early-Stage Pancreatic Cancer. April 24-27, Annapolis, Maryland. Abstracts.

Authors: 
Journal:  Int J Pancreatol       Date:  1994 Oct-Dec

3.  Derivation of ductlike cell lines from a transplantable acinar cell carcinoma of the rat pancreas.

Authors:  O S Pettengill; R A Faris; R H Bell; E T Kuhlmann; D S Longnecker
Journal:  Am J Pathol       Date:  1993-07       Impact factor: 4.307

4.  Effects of cholecystokinin octapeptide on a pancreatic acinar carcinoma in the rat.

Authors:  A Hajri; C Damgé
Journal:  Pharm Res       Date:  1998-11       Impact factor: 4.200

Review 5.  Gastrointestinal hormones as potential adjuvant treatment of exocrine pancreatic adenocarcinoma.

Authors:  W E Fisher; P Muscarella; L G Boros; W J Schirmer
Journal:  Int J Pancreatol       Date:  1998-12

6.  Protective effect of Emilia sonchifolia (L.) against high protein diet induced oxidative stress in pancreas of Wistar rats.

Authors:  Dominic Sophia; Paramasivam Ragavendran; Chinthamony Arul Raj; Velliyur Kanniappan Gopalakrishnan
Journal:  J Pharm Bioallied Sci       Date:  2012-01

7.  Expression of receptors for gut peptides in human pancreatic adenocarcinoma and tumour-free pancreas.

Authors:  C Tang; I Biemond; G J Offerhaus; W Verspaget; C B Lamers
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 8.  The Role of Gastrin and CCK Receptors in Pancreatic Cancer and other Malignancies.

Authors:  Jill P Smith; Lionel K Fonkoua; Terry W Moody
Journal:  Int J Biol Sci       Date:  2016-01-28       Impact factor: 6.580

Review 9.  Recent results in animal models of pancreatic carcinoma: histogenesis of tumors.

Authors:  D S Longnecker; V Memoli; O S Pettengill
Journal:  Yale J Biol Med       Date:  1992 Sep-Oct
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.